Redx Pharma Quits London Stock Exchange's AIM
By
Marcello Serrano
1 min read
⚠️ Heads up: this article is from our "experimental era" — a beautiful mess of enthusiasm ✨, caffeine ☕, and user-submitted chaos 🤹. We kept it because it’s part of our journey 🛤️ (and hey, everyone has awkward teenage years 😅).
Biotech company Redx Pharma Plc has announced its decision to pull its shares from the London Stock Exchange's smallest market, citing liquidity constraints and expressing its belief that it will be more appealing to investors as a private entity. This move is indicative of a broader trend where innovative biotech companies are increasingly choosing to sell shares in New York or relocate their listings there, as evidenced by companies such as Barinthus Biotherapeutics, Zura Bio, and OKYO Pharma. The shift raises questions about the attractiveness and potential benefits of the US markets compared to their counterparts in London.